Published in J Control Release on August 23, 2007
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release (2011) 1.59
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. J Control Release (2013) 1.42
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm (2011) 1.20
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity. Bioconjug Chem (2012) 1.00
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. Int J Nanomedicine (2012) 0.90
The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. Biomaterials (2012) 0.88
Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res (2011) 0.84
Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine (2012) 0.83
Targeted delivery of doxorubicin-loaded poly (ε-caprolactone)-b-poly (N-vinylpyrrolidone) micelles enhances antitumor effect in lymphoma. PLoS One (2014) 0.81
Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int J Nanomedicine (2012) 0.80
Synthesis and Self-Assembly of a Mikto-Arm Star Dual Drug Amphiphile Containing both Paclitaxel and Camptothecin. J Mater Chem B Mater Biol Med (2014) 0.80
Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles. World J Gastroenterol (2010) 0.78
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. J Cancer Ther (2012) 0.77
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells. Mol Ther (2017) 0.77
Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharm (2014) 0.76
EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Biomacromolecules (2015) 0.75
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci (2009) 2.63
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater (2009) 2.43
Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev (2012) 2.26
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
Metal-organic frameworks in biomedicine. Chem Rev (2011) 1.93
Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev (2013) 1.43
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol (2005) 1.38
Squalenoyl nanomedicines as potential therapeutics. Nano Lett (2006) 1.28
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev (2003) 1.25
Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev (2009) 1.25
Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine (2007) 1.21
Nanotheranostics for personalized medicine. Adv Drug Deliv Rev (2012) 1.19
BioMOFs: metal-organic frameworks for biological and medical applications. Angew Chem Int Ed Engl (2010) 1.16
Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials (2003) 1.15
Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther (2002) 1.12
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm (2004) 1.08
Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem (2005) 1.03
"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev (2004) 1.01
Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des (2005) 1.01
A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci (2009) 1.01
Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis (2007) 1.00
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine (2011) 0.99
Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des (2008) 0.99
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine (2011) 0.98
Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release (2004) 0.98
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm (2007) 0.98
Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol (2004) 0.98
Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem (2012) 0.97
Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res (2006) 0.96
Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir (2008) 0.95
Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm (2005) 0.95
Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci (2002) 0.95
Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target (2009) 0.95
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano (2011) 0.94
Role of gut macrophages in mice orally contaminated with scrapie or BSE. Int J Pharm (2005) 0.93
Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules (2007) 0.92
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano (2012) 0.91
Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. Int J Pharm (2003) 0.90
Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci (2002) 0.90
Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm (2006) 0.90
Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem (2011) 0.90
Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc Chem Res (2010) 0.90
Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther (2008) 0.89
Squalenoylation: a generic platform for nanoparticular drug delivery. J Control Release (2011) 0.88
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos (2008) 0.88
Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res (2003) 0.88
Cationic vectors in ocular drug delivery. J Drug Target (2004) 0.87
Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm (2009) 0.87
A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm (2005) 0.87
PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano (2012) 0.86
Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun (Camb) (2010) 0.86
Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids (2004) 0.85
Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials (2004) 0.84
Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J Control Release (2006) 0.84
Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. ACS Nano (2012) 0.84
Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res (2011) 0.84
Nanotechnology for therapy and imaging of liver diseases. J Hepatol (2011) 0.84
Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models. J Drug Target (2007) 0.84
Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. Nanoscale (2010) 0.83
Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules (2010) 0.83
Specific antitumor targetable beta-cyclodextrin-poly(ethylene glycol)-folic acid drug delivery bioconjugate. Bioconjug Chem (2004) 0.83
Sustained delivery of growth factors from methylidene malonate 2.1.2-based polymers. Biomaterials (2005) 0.83
High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-beta-cyclodextrin. Chemistry (2008) 0.83
Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials (2013) 0.82
Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. Langmuir (2011) 0.82
Polymer-based nanoparticles for the delivery of nucleoside analogues. J Nanosci Nanotechnol (2006) 0.82
Physico-chemical characterization of polysaccharide-coated nanoparticles. J Control Release (2005) 0.82
Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation. Bioconjug Chem (2010) 0.82
Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model. Oligonucleotides (2006) 0.81
Synthesis and physicochemical characterization of new squalenoyl amphiphilic gadolinium complexes as nanoparticle contrast agents. Org Biomol Chem (2011) 0.81
New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm Res (2010) 0.81
Supramolecular organization of S12363-liposomes prepared with two different remote loading processes. Biochim Biophys Acta (2008) 0.81
Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery. Bioconjug Chem (2013) 0.81
Consequences of ions and pH on the supramolecular organization of sphingomyelin and sphingomyelin/cholesterol bilayers. Chem Phys Lipids (2008) 0.81
Synthesis of poly(alkyl cyanoacrylate)-based colloidal nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.81
Towards an improved anti-HIV activity of NRTI via metal-organic frameworks nanoparticles. Adv Healthc Mater (2013) 0.80
Cyclodextrin and polysaccharide-based nanogels: entrapment of two hydrophobic molecules, benzophenone and tamoxifen. Biomacromolecules (2009) 0.80
siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res (2007) 0.80
Protein driven patterning of self-assembled cubosomic nanostructures: long oriented nanoridges. J Phys Chem B (2005) 0.80
Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy. Cancer Lett (2012) 0.80
Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. Thyroid (2014) 0.80